Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2005

01-10-2005 | Commentary

Treatment of solid tumors with immunotoxins

Authors: Davorka Messmer, Thomas J Kipps

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin are but a few of the factors that govern the effectiveness of these compounds in the treatment of patients with cancer. Improvements in design, synthesis, and delivery of these molecules may permit them to become significant components in the arsenal of targeted therapies for cancer.
Literature
1.
von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran S-E, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, et al: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7: R617-R626. 10.1186/bcr1264.CrossRefPubMedPubMedCentral
2.
Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE: Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992, 52: 6310-6317.PubMed
3.
Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE: EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 1995, 60: 137-144.CrossRefPubMed
4.
Ehrlich P: The relationship between chemical constitution, distribution, and pharmacological action. The Collected Papers of Paul Ehrlich. Edited by: Himmelweit F, Marquardt M, Dale H. 1956, Elmsford, NY: Pergamon Press, 1: 596-
5.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed
6.
Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, Roth JA: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 1989, 49: 4968-4971.PubMed
7.
Park JB, Rhim JS, Park SC, Kimm SW, Kraus MH: Amplification, overexpression, and rearrangement of the erbB-2 protoonco-gene in primary human stomach carcinomas. Cancer Res. 1989, 49: 6605-6609.PubMed
8.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Baja-monde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
9.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 719-726. 10.1200/JCO.20.3.719.CrossRefPubMed
10.
Hinoda Y, Sasaki S, Ishida T, Imai K: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. 2004, 95: 621-625.CrossRefPubMed
11.
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998, 16: 2659-2671.CrossRefPubMed
12.
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002, 20: 1215-1221. 10.1200/JCO.20.5.1215.CrossRefPubMed
13.
Arnon R, Sela M: In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev. 1982, 62: 5-27.CrossRefPubMed
14.
Wargalla UC, Reisfeld RA: Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA. 1989, 86: 5146-5150.CrossRefPubMedPubMedCentral
15.
16.
Hall WA, Fodstad O: Immunotoxins and central nervous system neoplasia. J Neurosurg. 1992, 76: 1-12.CrossRefPubMed
17.
Pastan I: Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother. 2003, 52: 338-341.PubMed
18.
Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I: Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res. 1999, 5: 2311-2315.PubMed
19.
Azemar M, Djahansouzi S, Jager E, Solbach C, Schmidt M, Maurer AB, Mross K, Unger C, von Minckwitz G, Dall P, et al: Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat. 2003, 82: 155-164. 10.1023/B:BREA.0000004371.48757.19.CrossRefPubMed
20.
Christiansen J, Rajasekaran AK: Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004, 3: 1493-1501.PubMed
21.
Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stocklin E, Wels W, Groner B: Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res. 1998, 58: 2661-2666.PubMed
Metadata
Title
Treatment of solid tumors with immunotoxins
Authors
Davorka Messmer
Thomas J Kipps
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1284

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue

Research article

Metastasis of hormone-independent breast cancer to lung and bone is decreased by α-difluoromethylornithine treatment

Review

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening

Research article

Impact of intercensal population projections and error of closure on breast cancer surveillance: examples from 10 California counties

Research article

Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro

Research article

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Review

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits